Skip to main content
SpringerLink
Log in

Multiple Sklerose und Impfungen

  • Conference paper
Multiple Sklerose

  • 227 Accesses

Zusammenfassung

Der Problemkreis „Multiple Sklerose und Impfungen“ ist vielschichtig und reicht von der möglichen Induktion der Erkrankung bzw. Schubauslösung durch eine Schutzimpfung bis zum potenziellen Einsatz rekombinatorischer Vakzine in der MS-Therapie. Im Folgenden sollen die wichtigsten Aspekte des Problemkreises schwerpunktmäßig anhand von vier Fragestellungen besprochen werden:

  1. 1.

    Welche Indikationen zur Schutzimpfung gelten für MS-Patienten?

  2. 2.

    Kann eine Schutzimpfung in suszeptiblen Individuen zur Erstmanifestation der MS und/oder zur Triggerung von MS-Schiiben beitragen?

  3. 3.

    Welche Besonderheiten gelten für Schutzimpfungen bei MS-Patienten unter immunsuppressiver bzw. immunmodulatorischer Therapie?

  4. 4.

    Lassen sich Impfstrategien für die Behandlung der MS einsetzen?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398–402.

    CAS  Google Scholar 

  • Albert LJ, Inman RD (1999) Molecular mimicry and autoimmunity. N Engl J Med 341:2068–2074.

    Article  PubMed  CAS  Google Scholar 

  • Ascherio A, Zhang SM, Herman MA, Olek MJ, Copian PM, Brodovicz K, Walker AM (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Eng J Med 344:327–332.

    Article  CAS  Google Scholar 

  • Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S, for the Vaccines in Multiple Sclerosis Study Group (2001) Vaccinations and the risk of relapse in multiple sclerosis. N Eng J Med 344:319–326.

    Article  Google Scholar 

  • Correale J, Lund B, McMillan M, Ko DY, McCarthy K, Weiner LP (2000) T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 107:130–139.

    Article  PubMed  CAS  Google Scholar 

  • Coustans M, Brunet P, deMarco O, LePage E, Chaperon J, Edan G (2000) Demyelinating disease and hepatitis B vaccination: Survey of 735 patients seen at MS clinic. Neurology 54 (Suppl 3):A165–A166.

    Google Scholar 

  • Currier RD, Meydrech EF, Currier MM (1996) Measles vaccination has had no effect on the occurrence of multiple sclerosis. Arch Neurol 53:1216–1217.

    PubMed  CAS  Google Scholar 

  • DeKeyser I (1998) Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 26:319.

    Article  CAS  Google Scholar 

  • DeKeyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51–53.

    Article  CAS  Google Scholar 

  • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589–593.

    CAS  Google Scholar 

  • Fenichel GM (1999) Assessment: Neurologic risk of immunization. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 52:1546–1552.

    CAS  Google Scholar 

  • Fujinami RS, Oldstone MB (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043–1045.

    Article  PubMed  CAS  Google Scholar 

  • Gaupp S, Härtung HP, Toyka K, Jung S (1997) Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens. J Neuroimmunol 79:129–137.

    Article  PubMed  CAS  Google Scholar 

  • Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, Smith L, Diveley J, Laxer JA (1997) Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV/?6 CDR2 peptide. J Neuroimmunol 76:29–38.

    Article  PubMed  Google Scholar 

  • Gran B, Hemmer B, Vergelli M, McFarland HF, Martin R (1999) Molecular mimicry and multiple sclerosis: degenerate T-cell recognition and the induction of autoimmunity. Ann Neurol 45:559–567.

    Article  PubMed  CAS  Google Scholar 

  • Gran B, Bielekova B, McFarland HF, Martin R (2000) Development of multiple sclerosis after hepatitis B vaccination: An immunologic case report. Neurology 54 (Suppl 3):A164.

    Google Scholar 

  • Herroelen L, DeKeyser I, Ebinger G (1991) Central-nervous system demyelination after immunization with recombinant hepatitis B vaccine. Lancet 338: 1174–1175.

    Article  PubMed  CAS  Google Scholar 

  • Jewell SD, Gienapp IE, Cox KL, Whitacre CC (1998) Oral tolerance as therapy for experi¬mental autoimmune encephalomyelitis and multiple sclerosis: demonstration of T cell an- ergy. Immunol Cell Biol 76:74–82.

    Article  PubMed  CAS  Google Scholar 

  • Kawai K, Sobue G (1998) Treatment of immunologic nervous system diseases by using anti-adhesion molecule antibodies. Nippon Naika Gakkai Zasshi 87:691–696.

    Article  PubMed  CAS  Google Scholar 

  • Kesselring J (1989) Multiple Sklerose. Kohlhammer, Stuttgart Berlin Kö, S 156

    Google Scholar 

  • Kollegger H, Schnied M, Zebenholzer K, Zeiler K, Hittmair K, Mallek R (1999) Vaccinations and steroids in MS: effects on disease progression and mood. Acta Neurol Scand 100:69–73.

    Article  PubMed  CAS  Google Scholar 

  • Li HL, Liu JQ, Bai XF, van der Meide PH, Link H (1998) Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalo-myelitis in Lewis rats. Immunology 94:431–437.

    Article  PubMed  CAS  Google Scholar 

  • Lisak RP (1998) Intravenous immunoglobulins in multiple sclerosis. Neurology 51 (Suppl 5):S25–S29.

    PubMed  CAS  Google Scholar 

  • Lopez E, Racadot E, Bataillard M, Berger E, Rumbach L (1999) Interferon gamma, IL2, IL4, ILIO and TNF-alpha secretions in multiple sclerosis patients treated with an anti-CD4 monoclonal antibody. Autoimmunity 29:87–92.

    Article  PubMed  CAS  Google Scholar 

  • Maassen CBM, Laman JD, Heijne den Bak-Glashouwer MJ et al. (1999) Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 17:2117–2128.

    Article  PubMed  CAS  Google Scholar 

  • Marshall E (1998) A shadow falls on hepatitis B vaccination effort. Science 281: 630–631.

    Article  PubMed  CAS  Google Scholar 

  • Martino G, Poliani PL, Marconi PC, Comi G, Furlan R (2000) Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors Gene Therapy 7:1087–1093.

    Google Scholar 

  • Miller AE, Morgante E, Buchwald LY et al. (1997) A multicenter randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48:312–314.

    PubMed  CAS  Google Scholar 

  • Möiling K (1998) Impfung und Gentherapie mit nackter DNA. Z Ärztl Fortbild Qual-Sich 92:681–683.

    Google Scholar 

  • Offner H, Adlard K, Zamora A, Vandenbark AA (2000) Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J Clin Invest 105:1465–1472.

    Article  PubMed  CAS  Google Scholar 

  • Quast U (1990) 100 und mehr knifflige Impffragen. Hippokrates, Stuttgart, S 122.

    Google Scholar 

  • Rieckmann P (2000) Einfluss von Impfungen und Infektionen auf Immunreaktionen. Aktiv (Organ der DMSG) 187:16–17.

    Google Scholar 

  • Ristori G, Buzzi MG, Sabatini U et al. (1999) Use of Bacille Calmette-Guèrin (BSG) in multiple sclerosis. Neurology 53:1588–1589.

    PubMed  CAS  Google Scholar 

  • Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen VA, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273–1281.

    PubMed  CAS  Google Scholar 

  • Ständige Impfkommission am Robert-Koch-Institut (2000) Impfempfehlungen. Epidemiologisches Bulletin 2:9–20.

    Google Scholar 

  • Steinman L (1991) Prospects for immunotherapy directed to the T cell receptor in human autoimmune disease. Ann N Y Acad Sci 636:147–153.

    Article  PubMed  CAS  Google Scholar 

  • Stinissen P, Zhang J, Medaer R, Vandevyver C, Raus J (1996) Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 45:500–511.

    Article  PubMed  CAS  Google Scholar 

  • Sturkenboom M, Wolfson C, Roullet E, Heinzlef O, Abenhaim L (2000) Demyelination, multiple sclerosis, and hepatitis B vaccination: A population-based study in the UK Neurology 54 (Suppl 3):A166.

    Google Scholar 

  • Tuohy VK, Mathisen PM (2000) T cell design for therapy in autoimmune demyelinating disease. J Neuroimmunol 107:226–232.

    Article  PubMed  CAS  Google Scholar 

  • Tsunoda I, Tolley ND, Theil DJ, Whitton JL, Kobayashi H, Fujinami RS (1999) Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA Brain Pathol 9:481–493.

    CAS  Google Scholar 

  • Vandenbark AA, Chou YK, Whitham R et al. (1996) Treatment of multiple sclerosis with T cell receptor peptides: results of a double-blind pilot trial. Nat Med 2:1109–1115.

    Article  PubMed  CAS  Google Scholar 

  • van Oosten BW, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune acti-vation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534.

    PubMed  Google Scholar 

  • Whitaker IN, Mitchell GW (1997) Clinical features of multiple sclerosis. In: Rain CS, McFarland HF, Tourtellotte WW (eds) Multiple Sclerosis. Clinical and pathogenetic basis. Chapman & Hall Medical, London Weinheim New York Tokyo Melbourne Madras, pp 3–19.

    Google Scholar 

  • Wildbaum G, Karin N (1999) Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experi-mental autoimmune encephalomyelitis. Gene Therapy 6:1128–1138.

    Article  PubMed  CAS  Google Scholar 

  • Wucherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695–705.

    Article  PubMed  CAS  Google Scholar 

  • Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N (2000) C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 106:361–371.

    Article  PubMed  CAS  Google Scholar 

  • Zipp F, Kerschensteiner M, Dornmair K, Malotka J, Schmidt S, Bender A, Giegerich G, deWaal Malefyt R, Wekerle H, Hohlfeld R (1998) Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain 121:1395–1407.

    Article  PubMed  Google Scholar 

  • Zipp F, Weil JG, Einhäupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5:964–965.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. Mix
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. K. Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Neurologie, Universität Rostock, Gehlsheimer Str. 20, 18055, Rostock, Germany

    Uwe K. Zettl  & Eilhard Mix PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Mix, E., Zettl, U.K. (2001). Multiple Sklerose und Impfungen. In: Zettl, U.K., Mix, E. (eds) Multiple Sklerose. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59453-3_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59453-3_36

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41121-5

  • Online ISBN: 978-3-642-59453-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation